This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Suntory Seen Near $1.6B GSK Drinks Deal

LONDON ( The Deal) -- Suntory Holdings' recently listed Suntory Beverage & Food is widely reported to be close to buying the Ribena and Lucozade drinks brands put up for sale by the U.K.'s GlaxoSmithKline (GSK - Get Report) in April.

The purchase, for an estimated 1 billion pounds ($1.6 billion), would mark a major push into Britain for the Japanese company, which became a significant force in Europe with its acquisition of France's Orangina from Blackstone Group (BX) and Lion Capital (LCHL) in 2009 for 300 billion yen ($3.01 billion).

In June, Suntory Beverage raised 388 billion yen in an initial public offering, with proceeds earmarked for a planned 500 billion yen acquisition drive as it seeks to double sales to 2 trillion yen by 2020 through overseas expansion.

The blackcurrant-flavored Ribena and Lucozade, a glaring-orange glucose drink, occupy a similar place in Britons' cultural consciousness to Orangina soda for the French. Lucozade, traditionally used as a pick-me-up during illness, has recently been chasing the sports and exercise drinks market. Pharma giant GlaxoSmithKline's April decision to sell the brands was a long time in the making. The British company at the same time also hived off around 50 older, or "tail," drugs brands with 2012 revenue of about 3 billion pounds into a separate unit which could be sold.

Beyond expanding Suntory's global empire and distribution reach, the deal should also reassure those who worry that the voracious appetite among Japanese companies for outbound acquisitions is diminishing because of the yen's retreat from historic highs. Yet Japan's banks have been active acquirers this year, particularly in Southeast Asia, and, only on Thursday, Otsuka Pharmaceutical agreed to pay $886 million for Dublin, Calif.-based Astex Pharmaceuticals.

Dealogic figures show that Japanese companies struck 416 outbound deals in the year to Sept. 6, down from 513 in the year-earlier period. The value of Japanese outbound acquisitions in the year to date was $27.8 billion, down from $56.8 billion in the corresponding 2012 period, when the year started with several big-ticket transactions. The value of outbound deals by Japanese banks in 2013 to date more than doubled year-on-year to $7.6 billion, Dealogic figures show. Separate figures from law firm Allen & Overy LLP found that Japan was the No. 6 outbound acquirer in the first half.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $42.91 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs